Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus

被引：3

作者：

Cressey, Tim R. ^{[1
,2
,3
]}

Harrison, Linda ^{[4
]}

Achalapong, Jullapong ^{[5
]}

Kanjanavikai, Prateep ^{[6
]}

Ayudhaya, Orada Patamasingh Na ^{[7
]}

Liampongsabuddhi, Prateung ^{[8
]}

Siriwachirachai, Thitiporn ^{[9
]}

Putiyanun, Chaiwat ^{[10
]}

Suriyachai, Pornnapa

Tierney, Camlin ^{[4
]}

Salvadori, Nicolas ^{[1
]}

Chinwong, Dujrudee ^{[11
]}

Decker, Luc ^{[12
]}

Tawon, Yardpiroon ^{[1
]}

Murphy, Trudy V. ^{[13
]}

Ngo-Giang-Huong, Nicole ^{[1
,2
,12
]}

Siberry, George K. ^{[14
]}

Jourdain, Gonzague ^{[1
,2
,11
]}

机构：

[1] Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, PHPT IRD, Chiang Mai, Thailand

[2] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA

[3] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England

[4] Harvard TH Chan Sch Publ Hlth, CBAR, Boston, MA USA

[5] Chiangrai Prachanukroh Hosp, Chiang Rai, Thailand

[6] Banglamung Hosp, Chon Buri, Thailand

[7] Nopparat Rajathanee Hosp, Bangkok, Thailand

[8] Lampang Hosp, Lampang, Thailand

[9] Khon Kaen Hosp, Khon Kaen, Thailand

[10] Chiang Kham Hosp, Phayao, Thailand

[11] Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Care, Chiang Mai, Thailand

[12] IRD, Unite Mixte Int PHPT 174, Chiang Mai, Thailand

[13] Ctr Dis Control & Prevent, Atlanta, GA USA

[14] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2018年 / 62卷 / 12期

关键词：

pregnancy; tenofovir; hepatitis B virus; pharmacokinetics; CLINICAL-PHARMACOLOGY; PHARMACOKINETICS; HIV;

D O I：

10.1128/AAC.01686-18

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC(0-24) was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.

引用

页数：5

共 16 条

[1] Pregnancy-Related Effects on Tenofovir Pharmacokinetics: a Population Study with 186 Women [J].

Benaboud, Sihem ;

Hirt, Deborah ;

Launay, Odile ;

Pannier, Emmanuelle ;

Firtion, Ghislaine ;

Rey, Elisabeth ;

Bouazza, Naim ;

Foissac, Frantz ;

Chappuy, Helene ;

Urien, Saik ;

Treluyer, Jean Marc .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (02) :857-862

[2] Pharmacokinetics of tenofovir during pregnancy and postpartum [J].

Best, B. M. ;

Burchett, S. ;

Li, H. ;

Stek, A. ;

Hu, C. ;

Wang, J. ;

Hawkins, E. ;

Byroads, M. ;

Watts, D. H. ;

Smith, E. ;

Fletcher, C. V. ;

Capparelli, E. V. ;

Mirochnick, M. .

HIV MEDICINE, 2015, 16 (08) :502-511

[3] The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women [J].

Colbers, Angela P. H. ;

Hawkins, David A. ;

Gingelmaier, Andrea ;

Kabeya, Kabamba ;

Rockstroh, Juergen K. ;

Wyen, Christopher ;

Weizsaecker, Katharina ;

Sadiq, S. Tariq ;

Ivanovic, Jelena ;

Giaquinto, Carlo ;

Taylor, Graham P. ;

Molto, Jose ;

Burger, David M. .

AIDS, 2013, 27 (05) :739-748

[4] Clinical Pharmacology Quality Assurance for HIV and Related Infectious Diseases Research [J].

DiFrancesco, R. ;

Tooley, K. ;

Rosenkranz, S. L. ;

Siminski, S. ;

Taylor, C. R. ;

Pande, P. ;

Morse, G. D. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (06) :479-482

[5] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].

Lampertico P. ;

Agarwal K. ;

Berg T. ;

Buti M. ;

Janssen H.L.A. ;

Papatheodoridis G. ;

Zoulim F. ;

Tacke F. .

JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398

[6]

Gilead Sciences Inc , 2017, VIREAD TEN DIS FUM P

[7]

Holford N., 2005, PAGE, V14

[8] Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B [J].

Jourdain, G. ;

Ngo-Giang-Huong, N. ;

Harrison, L. ;

Decker, L. ;

Khamduang, W. ;

Tierney, C. ;

Salvadori, N. ;

Cressey, T. R. ;

Sirirungsi, W. ;

Achalapong, J. ;

Yuthavisuthi, P. ;

Kanjanavikai, P. ;

Ayudhaya, O. P. Na ;

Siriwachirachai, T. ;

Prommas, S. ;

Sabsanong, P. ;

Limtrakul, A. ;

Varadisai, S. ;

Putiyanun, C. ;

Suriyachai, P. ;

Liampongsabuddhi, P. ;

Sangsawang, S. ;

Matanasarawut, W. ;

Buranabanjasatean, S. ;

Puernngooluerm, P. ;

Bowonwatanuwong, C. ;

Puthanakit, T. ;

Klinbuayaem, V. ;

Thongsawat, S. ;

Thanprasertsuk, S. ;

Siberry, G. K. ;

Watts, D. H. ;

Chakhtoura, N. ;

Murphy, T. V. ;

Nelson, N. P. ;

Chung, R. T. ;

Pol, S. ;

Chotivanich, N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (10) :911-923

[9] Tenofovir disoproxil fumarate - Clinical pharmacology and pharmacokinetics [J].

Kearney, BP ;

Flaherty, JF ;

Shah, J .

CLINICAL PHARMACOKINETICS, 2004, 43 (09) :595-612

[10] Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures [J].

Lavanchy, D .

JOURNAL OF VIRAL HEPATITIS, 2004, 11 (02) :97-107

← 1 2 →